Oral modified release T3 (triiodothyronine)

ENDORIZ AB has the objective to develop hormone replacement therapies in endocrinology within areas with unmet medical needs. First product an oral modified release T3 (triiodothyronine) for patients with thyroid hormone deficiency,

GUV Contact: Sara Lorenzon